BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37605488)

  • 1. Prevention and management of drug-induced osteonecrosis of the jaws using platelet-rich fibrin: A clinical feasibility study.
    Alrmali A; Saleh MHA; Kurdi SMS; Sabri H; Meghil MM; Wang HL
    Clin Exp Dent Res; 2023 Oct; 9(5):791-798. PubMed ID: 37605488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of Platelet-rich Fibrin in the management of medication-related osteonecrosis of the jaw: A case series.
    Fernando de Almeida Barros Mourão C; Calasans-Maia MD; Del Fabbro M; Le Drapper Vieira F; Coutinho de Mello Machado R; Capella R; Miron RJ; Gomes Alves G
    J Stomatol Oral Maxillofac Surg; 2020 Feb; 121(1):84-89. PubMed ID: 30794883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promising results of surgical management of advanced medication related osteonecrosis of the jaws using adjunctive leukocyte and platelet rich fibrin.
    Özalp Ö; Yıldırımyan N; Öztürk C; Kocabalkan B; Şimşek Kaya G; Sindel A; Altay MA
    BMC Oral Health; 2021 Dec; 21(1):613. PubMed ID: 34852823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of advanced-platelet rich fibrin (A-PRF) and injectable-platelet rich fibrin (i-PRF) in the management of a massive medication-related osteonecrosis of the jaw (MRONJ): A 5-years follow-up case report.
    Giudice A; Antonelli A; Muraca D; Fortunato L
    Indian J Dent Res; 2020; 31(5):813-818. PubMed ID: 33433526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of fibrin-rich platelets and leukocytes (L-PRF) in tissue repair in surgical oral procedures in patients using zoledronic acid-case-control study.
    Parise GK; Costa BN; Nogueira ML; Sassi LM; Schussel JL
    Oral Maxillofac Surg; 2023 Sep; 27(3):507-512. PubMed ID: 35739366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complementarity of surgical therapy, photobiomodulation, A-PRF and L-PRF for management of medication-related osteonecrosis of the jaw (MRONJ): an animal study.
    Jamalpour MR; Shahabi S; Baghestani M; Shokri A; Jamshidi S; Khazaei S
    BMC Oral Health; 2022 Jun; 22(1):241. PubMed ID: 35717177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Leukocyte-rich and Platelet-rich Fibrin (L-PRF) Adjunct to Surgical Debridement in the Treatment of Stage 2 and 3 Medication-Related Osteonecrosis of the Jaw.
    Yalcin-Ülker GM; Duygu G; Tanan G; Cakir M; Meral DG
    J Craniofac Surg; 2023 May; 34(3):1039-1044. PubMed ID: 36627754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteonecrosis of the jaw induced by bisphosphonates therapy in bone metastases patient: Case report and literature review.
    Hao L; Tian Z; Li S; Yan K; Xue Y
    Oral Oncol; 2022 May; 128():105852. PubMed ID: 35439709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventions for managing medication-related osteonecrosis of the jaw.
    Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous platelet-rich fibrin injections in the management of facial cutaneous sinus tracts secondary to medication-related osteonecrosis of the jaw.
    Bennardo F; Bennardo L; Del Duca E; Patruno C; Fortunato L; Giudice A; Nisticò SP
    Dermatol Ther; 2020 May; 33(3):e13334. PubMed ID: 32219975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of platelet-rich fibrin in the surgical treatment of medication-related osteonecrosis of the jaw: 40 patients prospective study.
    Zelinka J; Blahak J; Perina V; Pacasova R; Treglerova J; Bulik O
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2021 Sep; 165(3):322-327. PubMed ID: 32597421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet rich fibrin in the management of medication-related osteonecrosis of the jaw: a clinical and histopathological evaluation.
    Inchingolo F; Cantore S; Dipalma G; Georgakopoulos I; Almasri M; Gheno E; Motta A; Marrelli M; Farronato D; Ballini A; Marzullo A
    J Biol Regul Homeost Agents; 2017; 31(3):811-816. PubMed ID: 28958140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Leukocyte- and Platelet-Rich Fibrin in the Treatment of Medication-Related Osteonecrosis of the Jaws.
    Maluf G; Caldas RJ; Silva Santos PS
    J Oral Maxillofac Surg; 2018 Jan; 76(1):88-96. PubMed ID: 28675810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication-related osteonecrosis of the jaw: Is autologous platelet concentrate application effective for prevention and treatment? A systematic review.
    Lopez-Jornet P; Sanchez Perez A; Amaral Mendes R; Tobias A
    J Craniomaxillofac Surg; 2016 Aug; 44(8):1067-72. PubMed ID: 27318752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Platelet-Rich Fibrin (PRF) in the Prevention of Medication-Related Osteonecrosis of the Jaw (MRONJ).
    Miranda M; Gianfreda F; Raffone C; Antonacci D; Pistilli V; Bollero P
    Biomed Res Int; 2021; 2021():4948139. PubMed ID: 34095295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of advanced-platelet rich fibrin (A-PRF) in the management of medication-related osteonecrosis of the jaw (MRONJ): A case report.
    Asfour MAR; Aljoujou AA; Saifo MS; Jabban HAL
    Clin Case Rep; 2023 Nov; 11(11):e8259. PubMed ID: 38028038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Refractory Medicine Related Osteonecrosis of Jaw With Piezosurgical Debridement and Autologous Platelet Rich Fibrin: Feasibility Study.
    Gurav S; Dholam KP; Singh GP
    J Craniofac Surg; 2022 May; 33(3):e226-e230. PubMed ID: 34310422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the Addition of Bone Morphogenetic Protein 2 to Platelet-Rich Fibrin Improve Healing After Treatment for Medication-Related Osteonecrosis of the Jaw?
    Park JH; Kim JW; Kim SJ
    J Oral Maxillofac Surg; 2017 Jun; 75(6):1176-1184. PubMed ID: 28042979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case reports of medication-related osteonecrosis of the jaw (MRONJ) treated with uncultured stromal vascular fraction and L-PRF.
    Bouland C; Meuleman N; Widelec J; Keiani-Mothlagh K; Voisin C; Lagneaux L; Philippart P
    J Stomatol Oral Maxillofac Surg; 2021 Apr; 122(2):212-218. PubMed ID: 32540361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of leukocyte and platelet-rich fibrin in the prevention of medication-related osteonecrosis of the jaw, in patients requiring dental extractions: an observational study.
    Besi E; Pitros P
    Oral Maxillofac Surg; 2024 Jun; 28(2):785-793. PubMed ID: 38182917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.